



Novel Researches on Diagnosis and Treatment of Melanoma

Guest Editors:

Dr. Roberta Giuffrida

Dr. Stefania Guida

Dr. Caterina Dianzani

Dr. Claudio Conforti

Deadline for manuscript
submissions:

31 December 2024

Message from the Guest Editors

Dear Colleagues,

Melanoma is the deadliest form of skin cancer, and it is thus critical to diagnose and treat it at the earliest stage of its development. In recent decades, enormous progress has been achieved in the diagnosis and treatment of melanoma.


Recent advancements in noninvasive diagnostic strategies have helped to increase sensitivity for the early detection of melanoma and reduce unnecessary surgical procedures, especially in patients with ambiguous melanocytic lesions.

Surgery remains the standard therapy in patients with a localized disease but is not curative for advanced melanoma. In the last ten years, developments in checkpoint inhibition and targeted therapy against melanoma have revolutionized the management of patients with advanced disease.

The aim of this Special Issue is to publish original research articles, reviews, hypotheses, communications and editorial letters to provide new insights into the diagnosis and treatment of melanoma.

Dr. Roberta Giuffrida
Dr. Stefania Guida
Dr. Caterina Dianzani
Dr. Claudio Conforti
Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)